BioJapan and Regenerative Medicine are twinned conferences featuring a large-scale exhibition, an extensive seminar schedule, and a patented online partnering system, which is uniquely positioned within Asia as a platform for bringing together key players in the bio and regen-med fields. BioJapan has played an important role in facilitating interaction between Japanese and global companies/organizations and stimulating new business opportunities for almost two decades.
Top business development, licensing, and alliance management professionals, R&D personnel, and biotech company executives from around the world will gather in Yokohama in October 2019 for the 21st iteration of BioJapan. Over 1,000 organizations from 34 countries are expected to participate in the event, to hold an anticipated 10,000 business meetings over the course of the three days.
Some of the event seminar speakers will include:
Dr Ziegelbauer Karl, Head of Open Innovation & Digital Technologies, Bayer AG
Dr Andrew Wong, Head, Johnson and Johnson INNOVATION – Asia Pacific
Otani Akiko, Takeda Pharmaceutical Company Limited
Dr Gurkeerat Singh, Vice President of Emerging Technology and Innovation, Japan and Asia, Eli Lilly and Company
A few of the seminar topics will include:
New medical innovation with gut microbes
Next Generation Antibody Drugs
Bio-venture Ecosystem in the age of Open Innovation2.0
Development of novel engineered T cell therapies
BioJapan is organized by Japan Bioindustry Association, Japan Health Sciences Foundation, Japan Association for Techno-innovation in Agriculture, Forestry and Fisheries, Japan Biological Informatics Consortium, Japan Association of Bioindustries Executives, Japan Pharmaceutical Manufacturers Association, NPO Kinki Bio-industry Development Organization, Research Institute of Innovative Technology for the Earth, & Forum for Innovative Regenerative Medicine.